Chronic Cluster Headache
1
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Monoclonal Antibody
1100%
+ 2 programs with unclassified modality
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Salvia BioElectronicsNetherlands - Eindhoven
2 programsPRIMUSN/A1 trial
The Salvia PRIMUS implantable neurostimulator SystemN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
TevaFremanezumab
Salvia BioElectronicsThe Salvia PRIMUS implantable neurostimulator System
Salvia BioElectronicsPRIMUS
Clinical Trials (3)
Total enrollment: 259 patients across 3 trials
A Study Comparing the Efficacy and Safety of Fremanezumab (TEV-48125) for the Prevention of Chronic Cluster Headache (CCH)
Start: Jan 2017Est. completion: Jul 2018259 patients
Phase 3Terminated
Response to Combined Trigeminal and Occipital Nerve Stimulation for the Preventive Treatment in Chronic Cluster Headache
Start: Dec 2025Est. completion: Oct 2028
N/ANot Yet Recruiting
REsponse to Combined SONS and ONS in Chronic Cluster HeadachE
Start: May 2023Est. completion: Apr 2026
N/AActive Not Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
2 companies competing in this space